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Yan Han 
ON THE USE OF MARKER STRATEGY DESIGN TO DETECT PREDICTIVE 
MARKER EFFECT IN CANCER IMMUNOTHERAPY 
            The marker strategy design (MSGD) has been proposed to assess and validate 
predictive markers for targeted therapies and immunotherapies. Under this design, 
patients are randomized into two strategies: the marker-based strategy, which treats 
patients based on their marker status, and the non-marker-based strategy, which 
randomizes patients into treatments independent of their marker status in the same way as 
in a standard randomized clinical trial. The strategy effect is then tested by comparing the 
response rate between the two strategies and this strategy effect is commonly used to 
evaluate the predictive capability of the markers. We show that this commonly used 
between-strategy test is flawed, which may cause investigators to miss the opportunity to 
discover important predictive markers or falsely claim an irrelevant marker as predictive. 
Then we propose new procedures to improve the power of the MSGD to detect the 
predictive marker effect. One is based on a binary response endpoint; the second is based 
on survival endpoints. We conduct simulation studies to compare the performance of the 
MSGD with the widely used marker stratified design (MSFD). Numerical studies show 
that the MSGD and MSFD has comparable performance. Hence, contrary to popular 
belief that the MSGD is an inferior design compared with the MSFD, we conclude that 
using the MSGD with the proposed tests is an efficient and ethical way to find predictive 
markers for targeted therapies.   
 
                                                                                                              Sha Cao, PhD, Chair 
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1. Introduction 
            The emergence of immunotherapy and targeted therapy has revolutionized the era 
of clinical oncology [1, 2]. One of the biggest challenges of immunotherapy is that it 
typically benefits only a subgroup of patients [3].  As a result, optimizing the treatment 
benefit of immunotherapy requires the identification of the predictive biomarker that can 
be used to foretell the differential efficacy of the immunotherapy based on the presence 
or absence of the marker, e.g.,  pembrolizumab is  approved by the Food and Drug 
Administration for the treatment of advanced melanoma and metastatic squamous and 
nonsquamous non-small cell lung cancer (NSCLC) whose tumors express programmed 
death ligand-1 (PD-L1), i.e., PD-L1 positive patients. 
Figure 1: Diagram of the marker strategy design (MSGD). 
            Several novel biomarker-guided clinical trial designs have been proposed to 
achieve this goal [4-10]. Among them, the marker strategy design (MSGD) has been 
proposed as a useful trial design for identifying and validating predictive markers [4-6].  
As shown in Figure 1, the MSGD randomizes patients to two strategies, namely, the  
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Figure 2: Diagram of the marker stratified design (MSFD). 
marker-based strategy and the non-marker-based strategy. Patients randomized to the 
marker-based strategy are treated (deterministically) based upon their biomarker statuses 
(e.g., patients with a marker-positive status receive the targeted treatment and those with 
a marker-negative status receive the standard treatment). Patients randomized to the non-
marker-based strategy are further randomized to different treatments independent of their 
marker statuses. Although measuring the biomarker profiles of patients randomized to the 
non-marker-based strategy is not required, in practice we often do so, prospectively or 
retrospectively, for the purpose of biomarker discovery and other correlation studies.  In 
this article, we assume that the biomarker is measured for all patients in the trial.  A 
series of clinical trials [11-13] has adopted the MSGD for evaluating and validating 
predictive marker effects. For example, by using the MSGD, the excision repair cross-
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complementing 1 (ERCC1) trial [11] found that the ERCC1 mRNA expression level 
might be a predictive marker for treating non-small cell lung cancer (NSCLC) patients 
with docetaxle plus gemcitabine (the p-value = 0.02) based on 444 patients with stage-IV 
NSCLC. 
            In addition to the MSGD, another biomarker-guided clinical trial design which 
has been widely used to identify and validate the predictive marker is the marker 
stratified design (MSFD) [4-6].  As shown in Figure 2, the MSFD stratifies patients into 
different subgroups based on the patients' biomarker profile and then randomizes the 
patients to receive either the targeted treatment or the standard treatment within each 
subgroup. Under the MSFD, the predictive biomarker effect is typically evaluated by 
comparing the difference in the treatment effects within the marker-positive subgroup to 
those within the marker-negative subgroup [14]. Under the MSGD, however, the most 
common approach to test the predictive marker is to compare the response rate (or hazard 
for survival outcome) between the marker-based and non-marker-based strategies using a 
t test (or log-rank test). If the response rate of the marker-based strategy is significantly 
higher than that of the non-marker-based strategy, the marker is claimed as the predictive 
marker. Mandrekar and Sargent [5] and Freidlin et al. [15] noted that the between-
strategy test has low statistical power to detect the predictive biomarker effect because a 
certain proportion of patients will receive the same treatment regardless of their 
assignment to the marker-based or non-marker-based strategies (e.g., some patients with 
a marker-positive status in both strategies will receive the targeted treatment), thereby 
diluting the differences between the two treatment strategies. Therefore, it is generally 
believed that the MSGD design is an inferior design compared with the MSFD [15]. 
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            In this thesis, we argue that the primary interest of MSGD is to evaluate the 
between-strategy effect, which does not necessarily equal to the predictive effect defined 
in the MSFD. Therefore, it is unfair to directly compare MSGD with MSFD as these two 
designs target for different objects. Actually, if the predictive marker effect rather than 
the between-strategy effect is the primary interest of a clinical trial, we prove in the 
following content that the commonly used between-strategy test by MSGD is indeed 
problematic. After that, we propose a new test to evaluate the true predictive marker 
effect under MSGD. Finally, we conduct simulation studies to compare MSGD with 
MSFD under the same definition of predictive marker. Our simulation results reveal that 
contrary to popular belief, the MSGD is not an inferior design and has plausible 
performance compared with the MSFD. 
            Our study is motivated by a colorectal cancer trial, which is being conducted at 
the Indiana University Melvin and Bren Simon Cancer Center. The biomarker used in 
this trial is the KRAS gene mutation. The MTA is a novel KRAS inhibitor and the 
standard treatment is radiotherapy. This trial is conducted under the MSGD. A total of 
210 patients with colorectal cancer are equally randomized to either the non-marker-
based strategy and marker-based strategy. Patients in the non-marker-based strategy are 
further equally randomized to receive either the MTA or the standard treatment. Patients 
in the marker-based strategy are treated according to their KRAS gene status. The 
patients without the KRAS gene mutation receive the standard treatment whereas the 
patients with the KRAS gene mutation receive the MTA. The purpose of this trial is to 
evaluate whether the KRAS gene is a predictive marker for patients with colorectal 
cancer. As the commonly used between-strategy test is problematic in detecting the 
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predictive effect, novel test is required to evaluate such effect, which inspires the research 
for this thesis.   
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2. Deficiency of the between-strategy test 
            We first use two numerical examples to illustrate that the between-strategy test 
adopted by the MSGD is fundamentally flawed to detect the predictive marker effect. 
Suppose that the patient population of interest consists of 20% marker-positive (M+) 
patients and 80% marker-negative (M-) patients. Assume that for the standard treatment, 
the response rates for the M+ and M- patients are the same, at a value of 0.4; and for the 
targeted treatment under investigation, the response rates for the M+ and M- patients are 
0.8 and 0.5, respectively. Clearly, M is a predictive marker because the M+ patients 
respond to the targeted treatment substantially more favorably than the M- patients.  
Now, we look at the response rate in the marker-based strategy and the non-marker-based 
strategy. As summarized in Table 1, in the marker-based strategy, M+ patients are 
assigned to the targeted treatment, and M- patients are assigned to the standard treatment. 
Thus, the overall average response rate for the marker-based strategy is 20%×0.8+ 80%× 
0.4=0.48. In the non-marker-based strategy, patients are equally randomized into the 
standard and targeted treatments. The average response rate is (0.8+0.4)/2=0.6 for the M+ 
patients and (0.5+0.4)/2=0.45 for the M- patients. Thus, the overall average response rate 
for the non-marker-based strategy treatment arm is 20%×0.6+ 80%× 0.45=0.48, which is 
the same as that of the marker-based strategy! This means that we will completely miss 
the predictive marker effect if we take the approach of the commonly used between-
strategy test. 
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Table 1: Examples to illustrate the deficiency of the between-strategy test. 
 Example 1: marker is predictive Example 2: marker is not predictive 
 Marker-based 
strategy 
Non-marker 
based strategy 
Marker-based 
strategy 
Non-marker 
based strategy 
Treatment M+ 
(20%) 
M-
(80%) 
M+ 
(20%) 
M-
(80%) 
M+ 
(20%) 
M-
(80%) 
M+ 
(20%) 
M-
(80%) 
Targeted 0.8 N/A 0.8 0.5 0.1 N/A 0.1 0.1 
Standard N/A 0.4 0.4 0.4 N/A 0.4 0.4 0.4 
Average 0.8 0.4 0.6 0.45 0.1 0.4 0.25 0.25 
Overall 0.48 0.48 0.34 0.25 
 
            The between-strategy test can also mislead investigators to falsely conclude that a 
marker is predictive when it actually is not. To see this, consider a case similar to the 
above example, but now the marker is not predictive, with the response rate of the 
targeted treatment being the same (0.1) for both the M+ and M- patients. In this case, as 
shown in Table 1, the overall average response rate in the marker-based strategy is 0.34, 
higher than the overall response rate in the non-marker-based strategy (i.e., 0.25). If we 
use the between-strategy test, we will draw an incorrect conclusion that the marker is 
predictive. 
            Mathematically, the deficiency of the between-strategy test stems from the fact 
that the treatment effect evaluated by the between-strategy test is actually not the 
predictive marker effect, except under certain restrictive conditions, as described in 
Theorem 1. The proof is provided in Appendix. 
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            Theorem 1 Let φ be the marker positive prevalence. For the binary endpoint, the 
between-strategy Z test is valid for testing the predictive marker effect only when φ=0.5; 
and for the time-to-event endpoint, the between-strategy log-rank test is valid for testing 
the predictive marker effect only when (1) there is no treatment effect or (2) there is no 
prognostic effect and φ=0.5. 
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3. New tests for detecting the predictive marker effect 
3.1 Binary endpoint 
            In this section, we describe new procedures that are generally valid for the MSGD 
to detect the predictive marker effect.  We first consider the binary response outcome. Let 
𝑝𝑝𝑗𝑗𝑗𝑗  denote the response rate for patients with marker status k who are receiving treatment 
j, where k=+/- denotes marker-positive/-negative, and j=1/0 denotes the targeted/standard 
treatment. 
            The treatment effects of the targeted agent (with respect to the standard treatment 
as a control) are given by 𝑝𝑝1+ − 𝑝𝑝0+ and 𝑝𝑝1− − 𝑝𝑝0− for M+ and M- patients, respectively. 
The predictive marker effect is defined as𝜃𝜃 = (𝑝𝑝1+ − 𝑝𝑝0+) − (𝑝𝑝1− − 𝑝𝑝0−), i.e., the 
difference in the treatment effect between M+ and M- patients, with 𝜃𝜃 = 0 representing 
that the marker is not predictive. We notice that this definition has also been used by the 
MSFD to define the predictive marker effect [4, 14]. Our goal here is to test 𝐻𝐻0: 𝜃𝜃 = 0 
versus 𝐻𝐻1: 𝜃𝜃 ≠ 0. We also aware that the definition of the predictive marker effect is not 
unique. Indeed, the predictive marker effect can also be defined as a treatment-marker 
interaction term in a logistic model [16, 17], which is beyond the scope of this article. 
            Let ?̂?𝑝𝑗𝑗𝑗𝑗 = 𝑚𝑚𝑗𝑗𝑗𝑗/𝑛𝑛𝑗𝑗𝑗𝑗 denote the observed response rate for patients with marker 
status k who are receiving the treatment j, where 𝑛𝑛𝑗𝑗𝑗𝑗  is the number of patients having 
marker status k who are receiving treatment j, and  𝑚𝑚𝑗𝑗𝑗𝑗  is the number of response among 
𝑛𝑛𝑗𝑗𝑗𝑗  patients. We propose to evaluate the predictive marker effect for the MSGD using the 
following Z test, 
𝑍𝑍 = (?̂?𝑝1+ − ?̂?𝑝0+) − (?̂?𝑝1− − ?̂?𝑝0−)
�
?̂?𝑝1+(1 − ?̂?𝑝1+)
𝑛𝑛1+
+ ?̂?𝑝0+(1 − ?̂?𝑝0+)𝑛𝑛0+ + ?̂?𝑝1−(1 − ?̂?𝑝1−)𝑛𝑛1− + ?̂?𝑝0−(1 − ?̂?𝑝0−)𝑛𝑛0−  
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which asymptotically follows a standard normal distribution under the null hypothesis 
that there is no predictive marker effect. Given a significance level of 𝛼𝛼, we declare that 
M is a predictive marker if |𝑍𝑍| > 𝑧𝑧𝛼𝛼/2 where 𝑧𝑧𝛼𝛼/2 is the upper 𝛼𝛼/2 quantile of a standard 
normal distribution.    
            It can be shown that under the alternative hypothesis 𝐻𝐻1: 𝜃𝜃 = 𝜃𝜃1, Z asymptotically 
follows a non-central normal distribution 𝑁𝑁(𝜏𝜏, 1) where 
𝜏𝜏 = 2√𝑛𝑛𝜃𝜃1
�3φ𝑝𝑝1+(1 − 𝑝𝑝1+) + φ𝑝𝑝0+(1 − 𝑝𝑝0+) + (1 − φ)𝑝𝑝1−(1 − 𝑝𝑝1−) + 3(1 − φ)𝑝𝑝0−(1 − 𝑝𝑝0−) 
Given the type I error α, the power of the test under 𝐻𝐻1 is given by Pr �|𝑍𝑍| > �Ф−1 �𝛼𝛼
2
��� ≈ Ф(Ф−1 �𝛼𝛼
2
� + |𝜏𝜏|). 
Hence, to achieve the power of 1-β, we require Ф−1 �𝛼𝛼
2
� + |𝜏𝜏| = Ф−1(1 − 𝛽𝛽), leading to 
the following sample size formula 
𝑛𝑛 = 14 �Ф−1(1 − 𝛽𝛽) −Ф−1 �𝛼𝛼2��2 [3φ𝑝𝑝1+(1 − 𝑝𝑝1+) + φ𝑝𝑝0+(1 − 𝑝𝑝0+) + (1 − φ)𝑝𝑝1−(1
− 𝑝𝑝1−) + 3(1 − φ)𝑝𝑝0−(1 − 𝑝𝑝0−)] 
            As most sample size calculations, the value of n depends on a variety of 
parameters. The values of these parameters can be estimated from historical data or 
provided by investigators based on their domain knowledge. If such prior information is 
not available, a pilot study may be needed to obtain initial estimates of the parameters. 
3.2 Survival endpoint 
            We now turn to the survival endpoints (e.g., progression-free survival or overall 
survival). Let 𝜆𝜆𝑗𝑗𝑗𝑗  denote the hazard rate for the patients with D=j and M=k, and 𝜃𝜃+ =log (𝜆𝜆1+/𝜆𝜆0+)  and 𝜃𝜃− = log (𝜆𝜆1−/𝜆𝜆0−) denote the log hazard ratio between the targeted 
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treatment and standard treatment for the M+ patients and M- patients, respectively.  That 
is, 𝜃𝜃+ and 𝜃𝜃− respectively represent the treatment effect of the targeted agent (with 
respect to the standard treatment as the control) for the M+ patients and M- patients. 
Then, the predictive marker effect can be defined as 𝜃𝜃 = 𝜃𝜃+ − 𝜃𝜃− with 𝜃𝜃 = 0 
representing no predictive marker effect. We are interested in testing 𝐻𝐻0: 𝜃𝜃 = 0 versus 
𝐻𝐻1: 𝜃𝜃 ≠ 0. 
            Let 𝑍𝑍�+ and 𝑍𝑍�− denote the standard log-rank test statistics of comparing the 
targeted treatment versus the standard treatment for M+ and M- patients, respectively; 
and let  φ   denote the prevalence of M+ patients. We propose to test the predictive 
marker effect using the following weighted log rank test, 
𝑍𝑍� = �1 −  φ 𝑍𝑍�+ − � φ 𝑍𝑍�− 
The asymptotic distribution of Z ̃ is described in Theorem 2. The proof is provided in 
Appendix.  
            Theorem 2 Let ∆ be the total number of events. Test statistic 𝑍𝑍� asymptotically 
follows 𝑁𝑁(0,1) under 𝐻𝐻0: 𝜃𝜃 = 0 (i.e., no predictive marker effect), and follows 
𝑁𝑁(�3(1−φ)φ∆𝜃𝜃1
4
, 1) under 𝐻𝐻0: 𝜃𝜃 = 𝜃𝜃1. 
            Along the same line as the binary endpoint, given the type I error α and type II 
error 𝛽𝛽, it can be shown that the sample size formula for the survival endpoint is 
∆= 16[Ф−1(1−𝛽𝛽)−Ф−1(𝛼𝛼/2)]2
3𝜃𝜃1
2φ(1−φ) . 
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4. Simulation studies 
            We carried out simulation studies to compare the performance of the proposed 
approaches with the commonly used between-strategy test under the MSGD. We 
considered three cases: (1) the marker has no predictive effect, which corresponds to the 
null scenario of no predictive marker effect; (2) the marker has only the predictive effect; 
and (3) the marker has both predictive and prognostic effects. The prognostic effect is a 
type of marker effect that is not affected by the treatment, e.g., tumor stage is often a 
prognostic marker, and patients with higher stages have poor outcomes, regardless of the 
treatment. Our purpose of the simulation was to evaluate the predictive marker effect 
only. Hence, case (1) was used to evaluate the empirical type I error rate, and cases (2) 
and (3) were used to evaluate the empirical power. Under each of the simulation 
configurations, we conducted 10,000 simulated trials to evaluate the type I error rate and 
power, with a nominal level of 5%. 
            Table 2 shows the results for the binary response outcome. The between-strategy 
test generally led to inflated type I error rates except when φ=0.5. For example, when 
φ=0.3, the response rate of the standard treatment is 0.1 for M+ and M- patients, the 
response rate of the targeted treatment is 0.4 for M+ and M- patients, and the type I error 
rate was inflated to $17.8%. In contrast, the proposed Wald test consistently yielded type 
I error rates around the nominal level of 5%. In terms of power, the proposed test 
significantly outperformed the between-strategy test. The power gain ranged from 30% to 
50%, depending on the size of the predictive marker effect. For example, when the true 
response rate of the standard treatment is 0.2 for M+ and M- patients and the true 
response rates of the targeted treatment are 0.6 and 0.1 for M+ and M- patients, given that 
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the prevalence of the M+ status is 30%, the power of the proposed test is 88.8%, while 
that of the between-strategy test is merely 33.5%. 
Table 2: Type I error rate and power (%) of the MSGD for evaluating the predictive 
marker effect under the proposed approach (pro.) and the between-strategy (str.) 
comparison when the outcome is a binary endpoint and n=200. 
True response rate Prevalence of M+ 
Standard Targeted 30% 50% 70% 
M+ M- M+ M- str. pro. str. pro. str. pro. 
0.1 0.1 0.2 0.2 7.2 4.9 5.3 5.1 7.3 5.1 
0.1 0.1 0.3 0.3 11.6 5.2 5.4 5.1 10.9 5.2 
0.1 0.1 0.4 0.4 17.8 4.8 5.2 4.9 15.9 5.3 
0.2 0.2 0.4 0.1 20.1 52.1 23.3 63.3 26.7 58.4 
0.2 0.2 0.5 0.1 26.7 73.8 35.2 83.8 43.7 80.6 
0.2 0.2 0.6 0.1 33.5 88.8 46.9 95.2 62.4 92.4 
0.2 0.2 0.7 0.1 40.1 95.9 60.4 98.9 77.8 98.1 
0.2 0.4 0.3 0.1 46.7 74.4 34.5 83.5 23.4 76.8 
0.2 0.4 0.4 0.1 52.9 88.1 47.1 94.3 41.2 90.6 
0.2 0.4 0.5 0.1 61.1 95.7 59.3 98.7 58.8 97.1 
0.2 0.4 0.6 0.1 68.9 98.9 72.0 99.8 75.9 99.3 
 
            Table 3 shows the results for the survival endpoint. We use the exponential 
distribution to generate the survival endpoint and specify a 20% censoring rate for each 
patient. The simulation results for the survival endpoint were similar to those for the 
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binary outcomes. That is, the between-strategy test inflated the type I error rate except 
when the M+ prevalence was φ=0.5, while the proposed test consistently yielded 
reasonable type I error rates close to the nominal value of 5%. Compared to the between-
strategy comparison, the power of the MSGD often more than doubled when using the 
proposed test. 
Table 3: Type I error rate and power (%) of the MSGD for evaluating the predictive 
marker effect under the proposed approach (pro.) and the between-strategy (str.) 
comparison when the outcome is a survival endpoint and n=200. 
True hazard Prevalence of M+ 
Standard Targeted 30% 50% 70% 
M+ M- M+ M- str. pro. str. pro. str. pro. 
0.5 0.5 0.25 0.25 13.7 4.7 4.8 4.6 12.7 5.3 
0.5 0.5 0.15 0.15 26.1 5.0 5.0 5.1 22.4 5.2 
0.3 0.3 0.10 0.10 26.7 5.4 5.4 5.2 17.5 4.9 
0.5 0.5 0.38 0.75 17.9 41.4 17.4 49.0 13.8 42.3 
0.5 0.5 0.25 0.75 24.1 79.7 35.0 87.5 35.5 78.6 
0.5 0.5 0.19 0.75 32.1 93.1 42.8 96.8 51.2 93.2 
0.5 0.5 0.15 0.75 38.9 98.0 48.2 99.2 62.1 97.6 
0.5 0.4 0.36 0.60 21.6 46.2 20.3 53.2 17.6 43.0 
0.5 0.4 0.30 0.60 22.0 65.5 23.8 73.0 27.5 62.2 
0.5 0.4 0.24 0.60 28.8 79.2 35.8 89.1 44.2 81.7 
0.5 0.4 0.16 0.60 39.2 96.6 50.0 99.3 58.2 96.7 
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            In addition to the MSGD, the MSFD can also be used to evaluate the predictive 
marker effect and it is popular belief that MSFD is much more powerful than the MSGD. 
However, we argue that such conclusion is arbitrary because the original MSGD actually 
evaluate the between-strategy effect. Therefore, to make a fair comparison, we conducted 
simulation studies to compare the MSGD with MSFD by using the same test proposed in 
this thesis. That is, both designs were targeted for the same predictive marker effect. 
Also, the between-strategy test was also used for the MSGD for the purpose of power 
comparison. In addition to the power evaluation, we also reported the number of response 
(for the binary response) and the median survival month (for the survival outcome) to 
investigate the individual ethics of these two designs.   
            Table 4 summarizes the simulation results for the binary response outcome with 
n=200. In terms of power comparison, the MSGD is less powerful mainly because the 
between-strategy test used. For example, given φ=0.3, when the true response rate of the 
standard treatment is 0.2 for M+ and M- patients and the true response rates of the 
targeted treatment are 0.4 and 0.1 for M+ and M- patients, if the between-strategy test is 
used, the MSGD is 42.9% less powerful than the MSFD. On the other hand, if the 
proposed test is used, then the MSGD is only 7% less powerful. Moreover, although the 
MSGD was still 5% to 10% less powerful than the MSFD with the proposed method, this 
design gets around 6 to 12 more patients’ response to the treatment, indicting the MSGD 
a more ethical design. This is because the MSGD allocates patients to more effective 
treatments based on their biomarker profiles in the marker-based strategy arm, thereby 
enhancing the ethics of the trial. As a tradeoff, the randomization in the MSGD is less 
balanced than the MSFD,  
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Table 4: Type I error rate, power (%) and the number of response (in brackets) of the 
MSGD and MSFD for evaluating the predictive marker effect under the between-strategy 
test and proposed test when the outcome is a binary response endpoint. 
True response rate Prevalence of M+ 
Standard Targeted 30% 70% 
M+ M- M+ M- MSGD MSFD MSGD MSFD 
 str. pro.  str. pro.  
0.3 0.2 0.4 0.3 7.3 5.2(56.0) 5.2(54.0) 7.4 4.9(65.9) 5.0(63.9) 
0.2 0.2 0.4 0.1 19.4 55.3(45.5) 62.3(38.9) 25.9 57.9(59.6) 70.7(51.0) 
0.2 0.2 0.5 0.1 27.2 73.8(49.9) 83.6(41.8) 44.9 80.2(70.0) 91.5(58.0) 
0.2 0.2 0.6 0.1 33.2 88.1(54.4) 95.5(44.9) 61.9 93.0(80.4) 98.4(64.9) 
0.4 0.2 0.6 0.1 17.9 44.2(57.5) 57.3(51.1) 24.1 54.7(87.5) 66.2(78.9) 
0.4 0.2 0.7 0.1 23.7 67.6(62.0) 81.3(53.9) 40.4 77.3(98.1) 90.3(86.0) 
0.4 0.2 0.8 0.1 30.3 86.2(66.5) 95.8(57.0) 60.5 91.6(108.6) 98.4(92.8) 
  
resulting in a slight power loss. The simulation results in Table 5 for the survival outcome 
were similar to those in Table 4. When the proposed method is used, the MSGD was only 
slightly less powerful than the MSFD, but the median survival month for the MSGD was 
2 to 10 months longer. Hence, these two designs yield comparable performance and the 
MSGD is particularly useful when the predictive marker effect is large. That is because, 
with a large effect size, both the MSGD and MSFD should be able to identify the 
predictive marker but the MSGD can benefit more patients enrolled in the trial.   
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Table 5: Type I error rate, power (%) and median survival month (in brackets) of the 
MSGD and MSFD for evaluating the predictive marker effect under the between-strategy 
test and proposed test when the outcome is a survival response endpoint. 
True hazard Prevalence of M+ 
Standard Targeted 30% 70% 
M+ M- M+ M- MSGD MSFD MSGD MSFD 
 str. pro.  str. pro.  
0.5 0.5 0.25 0.25 14.0 5.0(27.1) 4.8(25.2) 12.1 4.9(29.0) 5.3(26.9) 
0.5 0.5 0.38 0.75 18.2 42.1(19.2) 51.8(17.3) 15.5 42.3(21.8) 51.6(19.9) 
0.5 0.5 0.25 0.75 27.9 78.6(20.6) 89.0(18.2) 37.4 78.7(26.6) 88.3(22.8) 
0.5 0.5 0.19 0.75 35.1 93.2(21.8) 98.3(19.0) 52.0 93.6(31.0) 98.0(25.0) 
0.4 0.5 0.24 0.60 14.5 42.9(22.1) 52.1(20.6) 22.3 42.8(28.8) 51.3(25.9) 
0.4 0.5 0.16 0.60 22.9 79.8(23.8) 89.1(21.6) 43.8 79.7(35.5) 89.2(29.5) 
0.4 0.5 0.12 0.60 29.4 93.6(25.0) 98.2(22.1) 57.2 93.3(41.0) 98.1(31.9) 
             
            As a side note, our results also indicate that the criticism that the MSGD is an 
inefficient design with low power to detect predictive markers [5, 15] is not completely 
valid. Low statistical power is not an inherent deficiency of the MSGD design itself, but 
simply caused by the use of an inappropriate statistical method (i.e., between-strategy 
test). When adopting the proposed test procedures, the MSGD can have significantly 
higher power to detect predictive markers. 
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5. Conclusion 
            The MSGD has been used in clinical trials to evaluate predictive marker effects. 
In this article, we show that, under the MSGD, the commonly used between-strategy test 
for assessing the predictive marker effect is fundamentally flawed. Such an approach not 
only suffers from low statistical power, but also potentially misleading results, e.g., 
falsely declaring that a marker is predictive when it is actually not. We propose new tests 
to be used with the MSGD for detecting the predictive marker effects. Numerical studies 
show that the proposed tests are generally valid and substantially more powerful than the 
between-strategy tests. Equipping the MSGD with the proposed tests provides clinicians 
a powerful design to detect predictive marker effects. Our simulation results also show 
that compared with the MSFD, the true power reduction by using the MSGD is at most 
10% but the MSGD is a more ethical design. Therefore, we conclude that the MSGD is 
not an inferior design and is especially useful when the predictive marker effect is large. 
The choice between the MSFD and MSGD depends on the trial setting and objectives. If 
power is of the biggest concern, the MSFD might be preferred. If investigators are 
interested in evaluating the real-world effect of the targeted therapy (i.e., the benefit of 
personalizing treatment by patient's biomarkers versus treating patients without using 
their biomarkers), the MSGD is clearly the choice. In addition, as the personalized 
treatment component of the MSGD may increase patient enrollment and retention, the 
MSGD is an attractive option when patient accrual is difficult, in particular given that the 
power loss of the MSGD is generally minor. 
            We have focused on the case in which the marker is measured for all patients 
prospectively or retrospectively. In principle, the MSGD does not require the 
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measurement of the marker for the patients randomized to the non-marker-based strategy. 
If this is the case, we can extend our methods to accommodate the missing marker 
information, for example, using the expectation-maximum algorithm. These extensions 
are statistically more involved and will be discussed elsewhere. 
            In conclusion, on the basis of the results of our study, the common approach of 
using the between-strategy test to detect predictive markers is problematic and has caused 
the misconception that the MSGD is an inefficient design with low statistical power. By 
using the proposed testing procedures, the MSGD provides a powerful and ethical 
clinical trial design to detect predictive markers. 
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Appendixes 
Appendix A: Proof of Theorem 1 
            We consider the binary endpoint first. For the equally randomized MSGD, the 
response rate for the marker-based strategy is 𝑝𝑝1+φ + 𝑝𝑝0−(1 − φ) and the response rate 
for the non-marker-based strategy is 0.5[(𝑝𝑝1+ + 𝑝𝑝0+)φ + (𝑝𝑝1− + 𝑝𝑝0−)(1 − φ)].  Hence,  
defining 𝜃𝜃∗ as the between-strategy difference, it can be expressed as 𝜃𝜃∗ =0.5[(1 − φ)𝜃𝜃 + (2φ− 1)(𝑝𝑝11 − 𝑝𝑝01)] and the conventional between-strategy method 
indeed tests the hypothesis 𝐻𝐻0: 𝜃𝜃∗ = 0 versus 𝐻𝐻1: 𝜃𝜃∗ ≠ 0 since in general we have 𝑝𝑝11 ≠
𝑝𝑝01. As a result, when θ = 0, 𝜃𝜃∗ = 0 only if φ = 0.5. That is, the between-strategy test is 
statistically valid only when the restrictive condition φ = 0.5 holds. 
            Similarly, for the survival endpoint, the hazard ratio at time t under the marker-
based strategy is 
𝜆𝜆00𝑒𝑒−𝜆𝜆00𝑡𝑡(1 − φ) + 𝜆𝜆11𝑒𝑒−𝜆𝜆11𝑡𝑡φ
𝑒𝑒−𝜆𝜆00𝑡𝑡(1 − φ) + 𝑒𝑒−𝜆𝜆11𝑡𝑡φ  
And the hazard ratio at time t under the non-marker-based strategy is 0.5𝜆𝜆00𝑒𝑒−𝜆𝜆00𝑡𝑡(1 − φ) + 0.5𝜆𝜆01𝑒𝑒−𝜆𝜆01𝑡𝑡φ + 0.5𝜆𝜆10𝑒𝑒−𝜆𝜆10𝑡𝑡(1 − φ) + 0.5𝜆𝜆11𝑒𝑒−𝜆𝜆11𝑡𝑡φ0.5𝑒𝑒−𝜆𝜆00𝑡𝑡(1 − φ) + 0.5𝑒𝑒−𝜆𝜆01𝑡𝑡φ + 0.5𝑒𝑒−𝜆𝜆10𝑡𝑡(1 − φ) + 0.5𝑒𝑒−𝜆𝜆11𝑡𝑡φ  
When θ = 0, these two hazard ratios are equivalent only if (1) there is no treatment effect 
or (2) there is no prognostic effect and φ=0.5. Therefore, for the survival endpoints, the 
between-strategy test is valid to detect the predictive marker effect only if one of these 
two restrictive conditions hold. 
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Appendix B: Proof of Theorem 2 
            For the survival endpoint, defining ∆ as the total number of events, according to 
Schoenfeld [18], we have 𝑍𝑍�−~𝑁𝑁(�3(1−φ)∆𝜃𝜃−4 , 1) and 𝑍𝑍�+~𝑁𝑁(�3φ∆𝜃𝜃+4 , 1). Hence, 𝑍𝑍� =
�1 − φ𝑍𝑍�+ − �φ𝑍𝑍�− has the following asymptotic distribution 
𝑍𝑍�~𝑁𝑁��3(1 − φ)φ∆(𝜃𝜃+ − 𝜃𝜃−)4 , 1� = 𝑁𝑁(�3(1 − φ)φ∆θ4 , 1) 
Then, under the null hypothesis 𝐻𝐻0: 𝜃𝜃 = 0, we have 𝑍𝑍�~𝑁𝑁(0,1), and under 𝐻𝐻1: 𝜃𝜃 = 𝜃𝜃1, 
we have 𝑍𝑍�~𝑁𝑁(�3(1−φ)φ∆𝜃𝜃1
4
, 1). 
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